🟢 Biovie is trading 5.83% up; no confirmed catalyst identified

Biovie is trading at $1.27, up 5.83%, with no confirmed catalyst identified.

• On October 19, Biovie announced presentation of Phase 2 Long COVID study results at the American Neurological Association meeting.
• The study showed exploratory benefits in certain symptom subgroups but did not achieve statistical significance on any endpoint in the overall trial population. The announcement does not establish a connection to the share-price move.
• Supplied market context is mixed for Biovie, and broader market sentiment does not clearly explain the gain.